Evidence map›Paper›PMID 37845409›Full record

ArticleThe international journal of cardiovascular imaging2024

Evaluation of cardiac findings in mucopolysaccharidosis.

Bahar Dehghan, Noushin Rostampour, Mohsen Sedighi, Mohammad Hosseini Saryazdi, Mohammad Jokar Rizi, Neda Mostofizadeh, Mahin Hashemipour, Mehri Khoshhali

Abstract read
PubMed Publisher
In one paragraph

Article in The international journal of cardiovascular imaging, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Natural History of Morquio A Syndrome.Journal of inherited metabolic disease · 2026
    Review
  2. Targeting Neurological Aspects of Mucopolysaccharidosis Type II: Enzyme Replacement Therapy and Beyond.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Bahar DehghanPediatric Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran.ORCID http://orcid.org/0000-0003-3684-8196
Noushin RostampourMetabolic Liver Diseases Research Center, Isfahan University of Medical Sciences, Isfahan, Iran. Rostampour_n@yahoo.com.
Mohsen SedighiTrauma and Injury Research Center, Iran University of Medical Sciences, Tehran, Iran.
Mohammad Hosseini SaryazdiSchool of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Mohammad Jokar RiziSchool of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Neda MostofizadehMetabolic Liver Diseases Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Mahin HashemipourMetabolic Liver Diseases Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Mehri KhoshhaliChild Growth and Development Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Isfahan University of Medical Sciences · IRIran University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeMucopolysaccharidoses (MPS) are a group of rare genetic diseases and heart involvement is one of the important conflicts in most types, which may cause serious complications. We used M-Mode and two-dimensional speckle tracking echocardiography (2D-STE) to explore cardiovascular involvements in MPS patients.

methodThe present cross-sectional study investigated the frequency of cardiac involvements in MPS patients. Included participants were MPS types I, II, III, IV, and VI who underwent specialized echocardiography exams to assess valvular function, systolic and diastolic function, left ventricular ejection fraction (LVEF), and global longitudinal strain (GLS).

results35 patients were enrolled in this study. The total mean age of patients was 9.58 ± 5.11 years and 71.4% were male. Type IV (40%) and type III (31.4%) were the most frequent MPS. Although LVEF did not differ notably among MPS types, GLS was significantly different (p = 0.029). Mitral regurgitation was observed remarkably more in MPS type III (p = 0.001) while mitral stenosis was more common in type III (p = 0.007). There was a significant association between LVEF and GLS (β= -0.662; p = 0.025) and between LVEF and MPS type (β = 1.82; p = 0.025) when adjusted for GLS.

conclusionCardiac complications are very common and are one of the most important causes of death in MPS patients. 2D-STE seems to be superior to M-Mode for detection of early and subclinical cardiac dysfunction in MPS patients.

Indexed as

Mitral Valve InsufficiencyMucopolysaccharidosesVentricular Dysfunction, LeftAdolescentChildChild, PreschoolCross-Sectional StudiesFemaleHumansMalePredictive Value of TestsStroke VolumeVentricular Function, LeftChildrenEchocardiographyHeartMucopolysaccharidoses

Identifiers

PMID37845409
OpenAlexW4387662441

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.